Literature DB >> 17078977

Rapid changes in the sensitivity of arcuate nucleus neurons to central ghrelin in relation to feeding status.

Victoria Scott1, Donna M McDade, Simon M Luckman.   

Abstract

Ghrelin, the endogenous ligand for the growth hormone secretagogue (GHS) receptor, stimulates feeding and increases body weight. Systemic ghrelin administration induces the immediate-early gene protein product, c-Fos, in the arcuate nucleus of the hypothalamus (ARC) of satiated rats and this increase is potentiated in fasted rats. The aim of this study was to determine whether potentiation was seen in fasted animals after intracerebroventricular (i.c.v) administration of ghrelin and to identify the hypothalamic nuclei activated by this peptide. In addition we investigated if allowing fasted animals to re-feed for 1 h prior to i.c.v. ghrelin injection affected the c-Fos response. Using c-Fos immunocytochemistry, we demonstrated that i.c.v. ghrelin activated several hypothalamic nuclei, including the ARC, paraventricular nucleus (PVH) and the lateral hypothalamus (LH). The c-Fos response was greater in fasted animals compared with satiated animals. Fasted rats allowed access to food for 1 h prior to central ghrelin administration showed an attenuated response in the ARC, similar to the response seen in fed animals. However, the response in the LH (including in the orexin neurons) was further potentiated. The latter may reflect a connection between the hypothalamus and regions of the brain responding to the reward value of the meal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078977     DOI: 10.1016/j.physbeh.2006.09.026

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  13 in total

Review 1.  The central nervous system sites mediating the orexigenic actions of ghrelin.

Authors:  B L Mason; Q Wang; J M Zigman
Journal:  Annu Rev Physiol       Date:  2013-10-02       Impact factor: 19.318

2.  Ghrelin's control of food reward and body weight in the lateral hypothalamic area is sexually dimorphic.

Authors:  Lorena López-Ferreras; Jennifer E Richard; Rozita H Anderberg; Fredrik H Nilsson; Kajsa Olandersson; Scott E Kanoski; Karolina P Skibicka
Journal:  Physiol Behav       Date:  2017-02-14

3.  Fourth ventricle injection of ghrelin decreases angiotensin II-induced fluid intake and neuronal activation in the paraventricular nucleus of the hypothalamus.

Authors:  Kimberly S Plyler; Derek Daniels
Journal:  Physiol Behav       Date:  2016-11-19

4.  Ghrelin inhibits visceral afferent activation of catecholamine neurons in the solitary tract nucleus.

Authors:  Ran Ji Cui; Xiaojun Li; Suzanne M Appleyard
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

5.  Nutritional state-dependent ghrelin activation of vasopressin neurons via retrograde trans-neuronal-glial stimulation of excitatory GABA circuits.

Authors:  Juhee Haam; Katalin C Halmos; Shi Di; Jeffrey G Tasker
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

6.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

7.  Caudal brainstem delivery of ghrelin induces fos expression in the nucleus of the solitary tract, but not in the arcuate or paraventricular nuclei of the hypothalamus.

Authors:  Lucy F Faulconbridge; Harvey J Grill; Joel M Kaplan; Derek Daniels
Journal:  Brain Res       Date:  2008-05-02       Impact factor: 3.252

Review 8.  Obesity Impairs the Action of the Neuroendocrine Ghrelin System.

Authors:  Jeffrey M Zigman; Sebastien G Bouret; Zane B Andrews
Journal:  Trends Endocrinol Metab       Date:  2015-11-02       Impact factor: 12.015

Review 9.  The cellular and molecular bases of leptin and ghrelin resistance in obesity.

Authors:  Huxing Cui; Miguel López; Kamal Rahmouni
Journal:  Nat Rev Endocrinol       Date:  2017-02-24       Impact factor: 43.330

Review 10.  Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.

Authors:  Gareth J Sanger; John B Furness
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-22       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.